Genocea Biosciences (NASDAQ: GNCA) announced that top-line results from a Phase 2a clinical trial for GEN-004, its universal vaccine candidate ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Hot FDA News Management Comments Trader Talk Trading Halts

FBR Capital Cuts Price Target After Genocea Biosciences (GNCA) Reports Disappointing GEN-004 Data October 19, 2015 1:22 PM Genocea Biosciences (GNCA) PT Lowered to $15 at Needham & CompanyOctober 19, 2015 10:03 AM Genocea Announces Top-Line Results from Phase 2a Trial for Universal Pneumococcal Vaccine Candidate GEN-004October 19, 2015 7:00 AM Genocea Biosciences (GNCA) halted with news pendingOctober 19, 2015 6:57 AM